KR102414267B1 - For antioxidant, antidepressant and antistress compositions comprising citrus unshiu peel extract - Google Patents
For antioxidant, antidepressant and antistress compositions comprising citrus unshiu peel extract Download PDFInfo
- Publication number
- KR102414267B1 KR102414267B1 KR1020200021186A KR20200021186A KR102414267B1 KR 102414267 B1 KR102414267 B1 KR 102414267B1 KR 1020200021186 A KR1020200021186 A KR 1020200021186A KR 20200021186 A KR20200021186 A KR 20200021186A KR 102414267 B1 KR102414267 B1 KR 102414267B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- antioxidant
- stress
- parts
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 54
- 239000000935 antidepressant agent Substances 0.000 title abstract description 48
- 239000003963 antioxidant agent Substances 0.000 title abstract description 45
- 230000002180 anti-stress Effects 0.000 title abstract description 44
- 230000001430 anti-depressive effect Effects 0.000 title abstract description 43
- 229940005513 antidepressants Drugs 0.000 title abstract description 40
- 241000555678 Citrus unshiu Species 0.000 title description 3
- 230000000694 effects Effects 0.000 claims abstract description 40
- 210000004207 dermis Anatomy 0.000 claims abstract description 31
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims description 14
- 240000004160 Capsicum annuum Species 0.000 claims description 11
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims description 11
- 235000007862 Capsicum baccatum Nutrition 0.000 claims description 11
- 239000001728 capsicum frutescens Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 244000269722 Thea sinensis Species 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 8
- 239000002304 perfume Substances 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 241000207923 Lamiaceae Species 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 235000015701 Artemisia arbuscula Nutrition 0.000 claims description 4
- 235000002657 Artemisia tridentata Nutrition 0.000 claims description 4
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 4
- 240000006891 Artemisia vulgaris Species 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229930014626 natural product Natural products 0.000 abstract description 8
- 230000001603 reducing effect Effects 0.000 abstract description 4
- 235000006708 antioxidants Nutrition 0.000 description 36
- 230000035882 stress Effects 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 230000002195 synergetic effect Effects 0.000 description 11
- 208000020016 psychiatric disease Diseases 0.000 description 9
- 239000003205 fragrance Substances 0.000 description 8
- 235000019629 palatability Nutrition 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 210000004209 hair Anatomy 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 5
- 241001164374 Calyx Species 0.000 description 5
- 108010093894 Xanthine oxidase Proteins 0.000 description 5
- 102100033220 Xanthine oxidase Human genes 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 210000000225 synapse Anatomy 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000013040 bath agent Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241001573881 Corolla Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- -1 norepinephrin Chemical compound 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009323 psychological health Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 230000000697 serotonin reuptake Effects 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- WCBPJVKVIMMEQC-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine Chemical group [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 WCBPJVKVIMMEQC-UHFFFAOYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000227166 Harrimanella hypnoides Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000006964 Perilla frutescens var acuta Nutrition 0.000 description 1
- 240000001979 Perilla frutescens var. acuta Species 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000002316 fumigant Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000009945 mood elevation Effects 0.000 description 1
- 230000008279 neurobiological mechanism Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008934 psychosocial wellbeing Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 진피 추출물을 포함하면서 항산화 효과를 나타낼 뿐만 아니라 스트레스 저감 효과와 우울증 예방 및 개선효과를 나타낼 수 있는 천연물 기반의 항산화, 항우울 및 항스트레스용 조성물을 제공하기 위한 것이다. 본 발명은 천연물을 기반으로 부작용의 문제없이 항산화, 항우울, 항스트레스 등의 효과를 나타낼 수 있도록 하면서 장기간 복용 또는 사용할 수 있는 조성물을 제공한다.An object of the present invention is to provide a composition for antioxidants, antidepressants and antistresses based on natural products, which can exhibit not only an antioxidant effect while including a dermis extract but also a stress reducing effect and a depression prevention and amelioration effect. The present invention provides a composition that can be taken or used for a long time while being able to exhibit effects such as antioxidant, antidepressant, and anti-stress without the problem of side effects based on natural products.
Description
본 발명은 진피 추출물을 포함하는 항산화, 항우울 및 항스트레스용 조성물에 관한 것이다. 보다 상세하게는 진피 추출물을 포함하면서 항산화 효과를 나타낼 뿐만 아니라 스트레스 저감 효과와 우울증 예방 및 개선효과를 나타낼 수 있는 천연물 기반의 항산화, 항우울 및 항스트레스용 조성물을 제공하기 위한 것이다. 또한 상기 조성물은 높은 기호성과 함께 일반식품, 기능성 식품, 기능성 향료 등으로 활용될 수 있다.The present invention relates to an antioxidant, antidepressant and antistress composition comprising a dermis extract. More specifically, it is to provide a composition for antioxidant, antidepressant and antistress based on natural products that can exhibit not only an antioxidant effect while including a dermis extract but also a stress reducing effect and depression prevention and amelioration effect. In addition, the composition can be used as general food, functional food, functional flavoring, etc. with high palatability.
현대 사회는 급격히 발전되고 다변화됨에 따라 현대인들에게 여러 가지 역할을 요구하며, 이에 따라 각종 스트레스로 인한 범불안 장애 및 정신질환을 호소하는 사람들이 증가하고 있다. 보건복지부가 발표한 「2016년도 정신질환실태 역학조사」에 따르면, 2016년 1년간 한가지 이상의 정신질환 경험 인구비율인 '정신질환 일년유병율'은 18세 이상 64세 이하의 성인 약 8명 중 1명인 12.1%로 나타났다. 또한, 2016년 현재 평생 동안 한 가지 이상의 정신질환 경험 인구비율인 '정신질환 평생유병율'도 성인 약 4명 중 1명인 26.6%로 나타났다.As modern society rapidly develops and diversifies, it demands various roles from modern people, and accordingly, the number of people complaining of generalized anxiety disorder and mental illness due to various stresses is increasing. According to the 「2016 Epidemiologic Survey of Mental Disorders」 released by the Ministry of Health and Welfare, the 'yearly prevalence of mental illness', which is the proportion of the population who experienced at least one mental illness in 2016, was 1 in 8 adults between the ages of 18 and 64. 12.1%. In addition, as of 2016, the 'lifetime prevalence of mental illness', which is the proportion of the population who experienced one or more mental disorders during their lifetime, was also found to be 26.6%, about one in four adults.
아울러, 최근 과도한 학구열 또는 각종 스트레스로 인해 청소년 정신질환이 증가하는 추세를 감안한다면, 전체 인구의 유병률은 더욱더 높다고 할 수 있다. 이러한 스트레스는 일상에 만연되어 있는 요소로 유발되고 거의 모든 정신과적 질환과 의학적 질병의 발생에 기여하며, 이에 성공적으로 대처하지 못하는 경우 우울, 불안, 피로, 분노, 기분변화와 같은 심리반응이 초래되고, 뇌파 중 α-파 감소, 혈압과 맥박수의 증가 등의 생리 반응을 초래하게 되는데 이러한 반응이 계속 반복되면 우울증, 불안증, 수면 장애와 같은 질병이 나타나고 개인, 가족 그리고 사회적 손실을 야기하며, 개인의 삶의 질을 낮추는 원인이 된다. 이와 관련하여 불안 및 우울의 예방 내지 치료를 위한 화합물들을 제시하고 있으나, 천연물을 이용하여 보다 안전하고 부작용이 적으면서도 효과적으로 불안, 우울 및 스트레스를 예방, 개선 내지 치료할 수 있는 물질의 개발이 여전히 요구되고 있다.In addition, considering the recent trend of increasing mental illness among adolescents due to excessive academic enthusiasm or various kinds of stress, the prevalence rate of the entire population can be said to be even higher. Such stress is induced by pervasive factors in daily life and contributes to the occurrence of almost all psychiatric and medical diseases. Physiological reactions such as decrease in α-wave during EEG, increase in blood pressure and pulse rate, etc. occur. If these reactions are repeated, diseases such as depression, anxiety, and sleep disorders appear, causing personal, family and social loss, and cause lower quality of life. In this regard, compounds for the prevention or treatment of anxiety and depression have been proposed, but there is still a need for the development of substances that can effectively prevent, improve or treat anxiety, depression and stress using natural products with fewer side effects and safer. have.
스트레스란 내부, 외부의 압력을 조정하고 그것에 적응하려는 각 개인의 심리적, 행동학적 반응을 총칭한다. 생존을 위협하는 실제적, 상징적, 가상적 스트레스요인의 영향력을 줄이기 위해 생체는 일련의 반응을 보이게 된다. 이 반응의 목적은 Claude Bernard가 내부 환경이라 일컬은 항상성을 유지하기 위한 것이다. 스트레스 요인은 개체의 평형을 깨뜨리는데, 개체는 이에 반응하여 생리적 반응을 일으킴으로써 이에 적응하고 항상성을 회복한다. 스트레스는 정신적 측면에서는 각성수준, 기억, 정서 등 심리적인 항상성의 변화를, 생물학적 측면에서는 뇌하수체-부신 축 활성화와 관련된 내분비계, 자율신경계, 면역계 등 다양한 생리적 변화를, 행동적 측면에서는 대처, 운동계 등 다양한 적응적 행동변화를 일으킨다. 스트레스반응은 기본적으로 생존을 위한 적응반응이지만, 지나치게 활성화되면 불안장애와 우울증의 증상을 야기할 수 있으며, 만성적으로 오랜기간 지속되면 신체적인 손상이 올 수도 있다. 따라서 스트레스와 관련된 질환의 병태생리와 관련해서 스트레스의 신경생물학적 기전을 탐구하는 연구가 오랫동안 진행되어 왔다.Stress refers to the psychological and behavioral responses of each individual to adjust and adapt to internal and external pressures. In order to reduce the influence of real, symbolic and hypothetical stressors that threaten survival, the living body shows a series of reactions. The purpose of this reaction is to maintain homeostasis, which Claude Bernard calls the internal environment. Stressors disrupt the individual's equilibrium, and the individual responds to this by generating a physiological response to adapt and restore homeostasis. Stress causes changes in psychological homeostasis such as arousal level, memory, and emotion in the psychological aspect, and various physiological changes such as the endocrine, autonomic nervous system, and immune system related to the activation of the pituitary-adrenal axis in the biological aspect, and coping, motor system, etc. in the behavioral aspect. It causes a variety of adaptive behavioral changes. The stress response is basically an adaptive response for survival, but excessive activation can cause symptoms of anxiety disorders and depression. Therefore, in relation to the pathophysiology of stress-related diseases, research to explore the neurobiological mechanism of stress has been in progress for a long time.
우울증은 객관적 상황과는 관계없이 일어나는 정서적 병리현상으로서 환자의 모든 생활이 우울한 기분으로 덮여 있고, 흥미가 감소하여 무쾌감증 (anhedonia)이 되며, 정신운동의 저하, 염세감, 절망에 사로잡히게 되는 정신적 질병이다. 또한, 식욕저하, 불면증, 변비, 성욕감퇴, 면역기능 저하로 인하여 질병에 대한 감수성이 높아지며, 이 밖에도 다양한 신체적 증상을 보인다. 당업계에서는 중추신경계의 시냅스 (synapse)내에 모노아민(monoamine)계 신경전달물질인 세로토닌 (serotonin), 노르에피네프린 (norepinephrin), 도파민 (dopamine) 등이 부족하게 되어 우울증이 유발된다는 것이 가장 유력한 가설로 여겨지고 있다.Depression is an emotional pathology that occurs irrespective of the objective situation, in which the patient's entire life is covered with a depressed mood, a decrease in interest becomes anhedonia, It is a mental illness. In addition, susceptibility to diseases increases due to decreased appetite, insomnia, constipation, decreased libido, and decreased immune function, and various other physical symptoms are also exhibited. The strongest hypothesis in the art is that depression is caused by a lack of monoamine-based neurotransmitters serotonin, norepinephrin, and dopamine in the synapse of the central nervous system. is considered
이에 따라, 대부분의 항우울제는 세로토닌 또는 노르아드레날린 시냅스에서 신경전달물질의 농도를 높이는 약리작용을 가지고 있다. 보다 구체적으로, 항우울제는 신경전달물질의 농도를 높여주는 메카니즘에 따라 크게 삼환계 항우울제 (Tricyclic antidepressants: TCA), 모노아민 옥시다제 억제제 (Monoamine oxidase inhibitor: MAOI), 또는 선택적 세로토닌 재흡수 억제제 (Selective serotonin reuptake inhibitor: SSRI) 등이 주로 사용되고 있다. 페넬진 (phenelzine) 등과 같은 모노아민 옥시다제 억제제는 심장병 유발이라는 심각한 부작용이 있기 때문에 최근에는 잘 쓰이고 있지 않으며, 이미프라민 등과 같은 삼환계 항우울제 역시 항콜린성 부작용 및 진정작용, 심혈관계에 대한 부작용이 상당한 문제점으로 남아 있다. 따라서, 최근에는 이와 같은 부작용이 적은 항우울제로서 선택적 세로토닌 (5-HT) 재흡수 저해제를 이용한 우울증 치료제의 개발에 초점을 두고 있으며, 그 대표적인 약제로서 플루옥세틴 (fluoxetine, 제품명; 푸로작), 파로세틴 (paroxetine, 제품명; 세로자트), 세르트랄린 (sertraline, 제품명; 졸로푸트) 등이 개발되어 임상적으로 그 효능을 널리 인정받고 있다.Accordingly, most antidepressants have a pharmacological action that increases the concentration of neurotransmitters at serotonin or noradrenaline synapses. More specifically, antidepressants are largely tricyclic antidepressants (TCA), monoamine oxidase inhibitors (MAOIs), or selective serotonin reuptake depending on the mechanism by which they increase the concentration of neurotransmitters. inhibitors: SSRIs) are mainly used. Monoamine oxidase inhibitors such as phenelzine have not been used recently because they have a serious side effect of inducing heart disease. remains a problem. Therefore, recently, as an antidepressant with fewer side effects, the focus is on the development of an antidepressant using a selective serotonin (5-HT) reuptake inhibitor. , product name; Seroxat) and sertraline (product name; Zoloft) have been developed and their efficacy is widely recognized clinically.
그러나, 이러한 세로토닌 재흡수 억제제 계열의 약물도, 전체 투약군 중에서 60% 정도의 환자에서만 효과가 있을 뿐, 나머지 30-40%정도의 환자에서는 치료적 효능을 나타내지 않고, 중추신경계 전체에 퍼져 있는 세로토닌계 시냅스 (serotonergic synapse)의 광범위한 영향으로 인해, 투약 환자에 따라 불필요한 부작용을 수반하는 문제점이 있다. 또한, 세로토닌계 약물반응에 있어서 대뇌 시냅스에서 세로토닌의 수준을 증가시키는데는 1시간 이 채 걸리지 않지만, 실제로 환자의 기분을 개선 (mood elevation)에 이르는 치료적 효능을 나타내기까지는 최소 3주 이상의 장기간 약물 복용이 필요하다는 점에서 그 한계가 있다.However, these serotonin reuptake inhibitor-type drugs are only effective in about 60% of patients in the total administration group, and do not show therapeutic efficacy in the remaining 30-40% of patients, and serotonin spreading throughout the central nervous system Due to the widespread influence of serotonergic synapse, there is a problem accompanying unnecessary side effects depending on the patient to be administered. In addition, in the serotonergic drug response, it takes less than 1 hour to increase the level of serotonin at cerebral synapses, but a long-term drug of at least 3 weeks or longer until it shows therapeutic efficacy that actually improves the patient's mood (mood elevation) It has its limitations in that it needs to be taken.
본 발명의 목적은 진피 추출물을 포함하면서 항산화 효과를 나타낼 뿐만 아니라 스트레스 저감 효과와 우울증 예방 및 개선효과를 나타낼 수 있는 천연물 기반의 항산화, 항우울 및 항스트레스용 조성물을 제공하기 위한 것이다.It is an object of the present invention to provide a composition for antioxidant, antidepressant and antistress based on natural products that can exhibit not only an antioxidant effect while including a dermis extract but also a stress reducing effect and depression prevention and amelioration effect.
본 발명의 목적은 천연물을 기반으로 부작용의 문제없이 항산화, 항우울, 항스트레스 등의 효과를 나타낼 수 있도록 하면서 장기간 복용 또는 사용할 수 있는 조성물을 제공하기 위한 것이다.It is an object of the present invention to provide a composition that can be taken or used for a long time while being able to exhibit effects such as antioxidants, antidepressants, and antistresses without any side effects based on natural products.
본 발명의 목적은 상기 조성물을 포함하는 일반 식품, 건강기능식품, 기호성 향료 등을 제공하기 위한 것이다.It is an object of the present invention to provide a general food, health functional food, palatable fragrance, etc. comprising the composition.
상기 목적을 달성하기 위하여, 본 발명의 일 실시예에 따른 항산화, 항우울 및 항스트레스용 조성물은 진피추출물을 포함하는 것이다.In order to achieve the above object, the composition for antioxidant, antidepressant and antistress according to an embodiment of the present invention is to include a dermis extract.
상기 항산화, 항우울 및 항스트레스용 조성물에 있어서, 상기 진피추출물은 물, C1 내지 C6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 추출 용매를 이용하여 추출되는 것일 수 있다.In the antioxidant, antidepressant and anti-stress composition, the dermis extract may be extracted using an extraction solvent selected from the group consisting of water, C 1 to C 6 lower alcohols, and mixtures thereof.
상기 항산화, 항우울 및 항스트레스용 조성물은 고춧잎 추출물을 더 포함하는 것일 수 있다.The antioxidant, anti-depressant and anti-stress composition may further include a red pepper leaf extract.
상기 항산화, 항우울 및 항스트레스용 조성물은 범꼬리풀 추출물을 더 포함하는 것일 수 있다.The antioxidant, anti-depressant and anti-stress composition may be one that further comprises an extract of Beomaceae.
상기 항산화, 항우울 및 항스트레스용 조성물은 차즈기 추출물을 더 포함하는 것일 수 있다.The antioxidant, antidepressant and antistress composition may further include a chazugi extract.
본 발명의 다른 일 실시예에 따른 일반 식품은 상기 항산화, 항우울 및 항스트레스용 조성물을 포함하는 것일 수 있다.General food according to another embodiment of the present invention may include the antioxidant, anti-depressant and anti-stress composition.
본 발명의 또 다른 일 실시예에 따른 기능성 식품은 상기 항산화, 항우울 및 항스트레스용 조성물을 포함하는 것일 수 있다.Functional food according to another embodiment of the present invention may include the antioxidant, anti-depressant and anti-stress composition.
본 발명의 또 다른 일 실시예에 따른 향료는 상기 항산화, 항우울 및 항스트레스용 조성물을 포함하는 것일 수 있다.A fragrance according to another embodiment of the present invention may include the antioxidant, antidepressant and antistress composition.
본 발명의 또 다른 일 실시예에 따른 외용제는 상기 항산화, 항우울 및 항스트레스용 조성물을 포함하는 것일 수 있다.The external preparation according to another embodiment of the present invention may include the antioxidant, antidepressant and antistress composition.
이하, 본 발명을 더욱 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 일 실시예에 따른 항산화, 항우울 및 항스트레스용 조성물은 진피추출물을 포함하는 것이다.Antioxidant, antidepressant and antistress composition according to an embodiment of the present invention is to include a dermis extract.
본 명세서 전체에서, '추출물'은 상술한 바와 같이 당엽계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 추출물은 상술한 추출용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예컨대, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 추출물에 포함되는 것이다.Throughout this specification, 'extract' has the meaning commonly used as a crude extract in the sugar leaf system as described above, but in a broad sense also includes a fraction obtained by additionally fractionating the extract. That is, the extract includes not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (prepared for separation according to size, charge, hydrophobicity or affinity), etc. The fraction obtained through the purification method is also included in the extract of the present invention.
본 명세서 전체에서, 어떤 부분이 어떤 구성요소를 "포함" 한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성 요소를 더 포함할 수 있는 것을 의미한다.Throughout this specification, when a part "includes" a certain component, it means that other components may be further included, rather than excluding other components, unless otherwise stated.
본 명세서 전체에서, 마쿠시 형식의 표현에 포함된 "이들의 조합"의 용어는 마쿠시 형식의 표현에 기재된 구성 요소들로 이루어진 군에서 선택되는 하나 이상의 혼합 또는 조합을 의미하는 것으로서, 상기 구성 요소들로 이루어진 군에서 선택되는 하나 이상을 포함하는 것을 의미한다.Throughout this specification, the term "combination of these" included in the expression of the Markush form means one or more mixtures or combinations selected from the group consisting of the components described in the expression of the Markush form, and the components It is meant to include one or more selected from the group consisting of.
본 명세서 전체에서, 용어 "예방" 이란, 조성물의 투여에 의해 관절염을 억제시키거나 발병을 지연시키는 모든 행위를 의미하며, "치료" 또는 "개선"이란, 조성물의 투여에 의해 증세가 호전되거나 이롭게 변경시키는 모든 행위를 의미한다.Throughout this specification, the term "prevention" refers to any action that suppresses or delays the onset of arthritis by administration of the composition, and "treatment" or "improvement" means that the symptoms are improved or beneficial by administration of the composition Any action that changes
본 발명에서 이용되는 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The extract used in the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze-drying or spray-drying.
본 발명에서 말하는 "항산화"는 활성산소의 저감 및 세포의 산화 또는 노화를 억제하는 효과를 나타내는 것을 말한다."Antioxidant" as used in the present invention refers to exhibiting the effect of reducing active oxygen and inhibiting oxidation or aging of cells.
본 발명에서 말하는 우울증은, 우울 장애(depressive disorder)라고도 하며, 이는 의욕 저하와 우울감을 주요 증상으로 하여 다양한 인지, 정신 또는 신체적 증상을 일으켜 일상 기능의 저하를 가져오는 질환을 말한다. 한편, 본 발명에서 말하는 "항우울"이란 위 우울증 또는 우울 장애를 예방 및 개선할 수 있고, 의욕저하 및 우울감을 개선하는 효과를 말한다.Depression as used in the present invention, also called depressive disorder, refers to a disease that causes a decrease in daily functioning by causing various cognitive, mental, or physical symptoms with a decrease in motivation and depression as the main symptoms. On the other hand, "anti-depression" as used in the present invention refers to the effect of being able to prevent and improve gastric depression or depressive disorder, and to improve motivation and depression.
본 발명에서 말하는 스트레스와 관련하여 이에 대한 정의는 학자들마다 약간씩 다르지만, 스트레스는 외부 자극에 의해 발생되는 유기체에 대한 해로운 반응 또는 변화를 의미한다. 일반적으로, 생체에 미치는 자극이 일정한 정도 이상이 될 경우 상해적으로 작용하는데, 이때 생체는 그 자극의 종류에 관계없이 일정한 위협에 대한 반응으로 긴장성 두통, 편두통, 고혈압, 소화불량, 피로, 통증, 발모 및 피부의 거칠어짐 등을 일으키고, 만성적으로 지속되면 각종 신경증, 위궤양 등을 유발시키는 등의 비특이적인 전신적증후군(general adaptive syndrome)을 나타내게 되는데, 이를 스트레스라 정의하고 있다(Selye, 1958, Longmans Green and Co.). 특히, 우울증과 같은 정신장애, 신경성위, 십이지장궤양 등과 같은 소화기장애, 스트레스성 갑상선기능항진증과 같은 내분비장애, 스트레스성 기미나 여드름 등과 같은 피부장애, 및 부정맥이나 협심증과 같은 심혈관계 장애 등의 다양한 질환이 스트레스로 인해 유발되는 것으로 보고되고 있다.The definition of stress in the present invention is slightly different for each scholar, but stress refers to a detrimental response or change to an organism caused by an external stimulus. In general, when the stimulus on the living body exceeds a certain level, it acts invasively. At this time, the organism responds to a certain threat regardless of the type of stimulus, such as tension headache, migraine, high blood pressure, indigestion, fatigue, pain, It causes hair growth and roughness of the skin, and if it continues chronically, it results in a nonspecific general adaptive syndrome, such as various neurosis and gastric ulcer, which is defined as stress (Selye, 1958, Longmans Green). and Co.). In particular, various diseases such as mental disorders such as depression, digestive disorders such as neurosis and duodenal ulcer, endocrine disorders such as stress hyperthyroidism, skin disorders such as stress spots or acne, and cardiovascular disorders such as arrhythmias or angina pectoris It has been reported that the disease is caused by stress.
본 발명에서 말하는 "항스트레스"는 상술한 스트레스 또는 스트레스에 의한 질환을 예방 또는 개선할 수 있도록 하는 효과를 말한다."Anti-stress" as used in the present invention refers to the effect of preventing or ameliorating the aforementioned stress or diseases caused by stress.
상기 진피(Citrus Unshiu Peel)는 운향과의 귤(Citrus unshiu Markovich)의 성숙한 과실의 껍질을 건조시킨 것을 의미한다. 방향성 건위약으로 위염, 소화불량 등에 쓰이며, 진토, 진해, 거담제로서 사용된다.The dermis (Citrus Unshiu Peel) means dried skins of mature fruits of Citrus unshiu Markovich. It is used for gastritis, indigestion, etc. as an aromatic dry placebo, and is used as an antitussive, antitussive, and expectorant.
상기 진피 추출물을 포함하는 경우 항산화 활성과 함께, 스트레스를 예방 및 완화하고 우울증을 예방 및 개선하는 효과를 나타낼 수 있다. 또한 상기 스트레스 예방 및 완화를 통하여 스트레스에 따라 발병할 수 있는 여러 질환을 예방 및 개선하는 효과를 낼 수 있다.When the dermis extract is included, it may exhibit an effect of preventing and alleviating stress and preventing and improving depression along with antioxidant activity. In addition, through the prevention and alleviation of stress, it is possible to prevent and improve various diseases that may be caused by stress.
상기 항산화, 항우울 및 항스트레스용 조성물에 있어서, 상기 진피 추출물은 물, C1 내지 C6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 추출 용매를 이용하여 추출되는 것일 수 있다.In the composition for antioxidant, antidepressant and antistress, the dermis extract may be extracted using an extraction solvent selected from the group consisting of water, C 1 to C 6 lower alcohols, and mixtures thereof.
바람직하게 상기 용매는 물, 에탄올 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나일 수 있다. 상기 용매에 의하는 경우 항산화, 항스트레스 및 항우울 효과를 나타내는 유효성분에 대한 수득률에 높게 유지될 수 있어 상대적으로 적은 함량에 비하여 보다 우수한 효과를 나타낼 수 있다.Preferably, the solvent may be any one selected from the group consisting of water, ethanol, and mixtures thereof. In the case of the solvent, the yield for the active ingredient exhibiting antioxidant, anti-stress and anti-depressant effects can be maintained at a high level, and thus a more excellent effect can be exhibited compared to a relatively small content.
상기 항산화, 항우울 및 항스트레스용 조성물은 고춧잎 추출물을 더 포함하는 것일 수 있다.The antioxidant, anti-depressant and anti-stress composition may further include a red pepper leaf extract.
상기 고춧잎은 고추(hot pepper)의 잎을 말한다.The red pepper leaf refers to a leaf of hot pepper.
상기 항산화, 항우울 및 항스트레스용 조성물은 범꼬리풀 추출물을 더 포함하는 것일 수 있다.The antioxidant, anti-depressant and anti-stress composition may be one that further comprises an extract of Beomaceae.
상기 범꼬리풀은 산골짜기 양지에서 자란다. 높이 30 내지 80cm이다. 뿌리줄기가 짧고 굵으며 잔뿌리가 많다. 뿌리에 달린 잎은 어긋나고 잎자루가 길며 넓은 달걀 모양이고 점차 좁아져서 끝이 뾰족하고 밑은 심장밑 모양이다. 잎 가장자리는 밋밋하고 뒷면은 흰빛이다. 잎 길이 5 내지 10cm, 나비 3 내지 7cm이다. 줄기에 달린 잎은 이와 비슷하지만 잎자루가 짧고 잎도 작다. 잎집은 막질(膜質: 얇은 종이처럼 반투명한 것)이다. 꽃은 6 또는 7월에 연분홍색 또는 흰색으로 피고 수상꽃차례에 달린다. 꽃잎은 없고 꽃받침은 5개로 갈라진다. 수술은 8개로 꽃받침보다 좀더 길고, 꽃밥은 연한 붉은빛을 띤 자주색이며 수술대 밑부분에 작은 샘[腺]이 있다. 열매는 수과로서 9 또는 10월에 익는데, 꽃받침에 싸이며 3개의 능선이 있다. 어린 잎과 줄기는 식용하고, 뿌리줄기는 열을 내리거나 경기(驚氣)를 다스리며 종기의 염증을 없애는 데 사용한다. 한국, 중국 동북부, 헤이룽강, 우수리강 등지에 분포한다.The pan-tailed grass grows in sunny places in mountain valleys. 30 to 80 cm in height. The rhizome is short and thick, and there are many fine roots. The leaf attached to the root is alternate phyllotaxis, the petiole is long, broad egg-shaped, gradually narrows and has a sharp tip, and the bottom is in the shape of a heart. The edge of the leaf is flat and the back side is white. Leaves are 5 to 10 cm long and 3 to 7 cm wide. The leaves on the stem are similar to this, but the petiole is short and the leaves are small. The sheath is membranous (膜質: translucent like thin paper). Flowers bloom in June or July in light pink or white, and hang on the inflorescence. There are no petals and the sepals are divided into 5 pieces. There are 8 stamens, longer than the calyx, the anthers are light reddish purple, and there is a small gland [腺] at the bottom of the stamens. Fruits are aqueous and ripen in September or October, are wrapped in calyx, and have 3 ridges. The young leaves and stems are edible, and the rhizomes are used to relieve heat, control competition, and eliminate inflammation of boils. It is distributed in Korea, northeastern China, Heilong River, and Ussuri River.
상기 항산화, 항우울 및 항스트레스용 조성물은 차즈기 추출물을 더 포함하는 것일 수 있다.The antioxidant, antidepressant and antistress composition may further include a chazugi extract.
상기 차즈기(Perilla frutescens var. acuta)는 줄기는 곧게 서고 높이가 20 내지 80cm이며 단면이 사각형이고 자줏빛이 돌며 향기가 있다. 잎은 마주나고 넓은 달걀 모양이며 끝이 뾰족하고 밑 부분이 둥글며 가장자리에 톱니가 있다. 잎 양면에 털이 있고, 뒷면 맥 위에는 긴 털이 있으며, 잎자루가 길다. 꽃은 8 또는 9월에 연한 자줏빛으로 피고 줄기와 가지 끝에 총상꽃차례를 이루며 달린다. 꽃받침은 털이 있고 2개로 갈라지며, 갈라진 조각 중 위쪽 것은 다시 3개로 갈라지고 아래쪽 조각은 다시 2개로 갈라진다. 화관은 짧은 통 모양이고 끝이 입술 모양을 이루며, 아랫입술이 윗입술보다 약간 길다. 수술은 4개인데, 그 중에 2개가 길다. 열매는 분과(分果: 분열과에서 갈라진 각 열매)이고 둥글며 지름이 1.5mm이고 꽃받침 안에 들어 있다.The chazugi (Perilla frutescens var. acuta) has a straight stem, a height of 20 to 80 cm, a square cross section, a purple color, and a fragrance. The leaves are opposite, broad egg-shaped, pointed at the tip, rounded at the bottom, and serrated at the edge. There are hairs on both sides of the leaves, long hairs on the veins on the back side, and long petioles. Flowers bloom in August or September in light purple and run in raceme at the ends of stems and branches. The calyx has hairs and is split into two, and the upper part of the split pieces is split into three again, and the lower piece is split into two again. The corolla is short, cylindrical, and the tip is lip-shaped, and the lower lip is slightly longer than the upper lip. There are 4 stamens, and 2 of them are long. The fruit is a branch (separate: each fruit divided from the fissionaceae), is round, has a diameter of 1.5mm, and is contained in a calyx.
상기 고춧잎, 범꼬리풀 및 차즈기 추출물을 더 포함하는 경우 항산화, 항우울 및 항스트레스에 대한 상승효과를 나타낼 수 있다.When the red pepper leaf, pantail grass and chazugi extract are further included, it may exhibit a synergistic effect on antioxidants, antidepressants and antistress.
바람직하기 상기 항산화, 항우울 및 항스트레스용 조성물은 진피 추출물을 포함하고, 상기 진피 추출물 100 중량부에 대하여 고춧잎 추출물 0.1 내지 20 중량부; 범꼬리풀 5 내지 50 중량부 및 차즈기 추출물 0.1 내지 20 중량부를 포함하는 것일 수 있다.Preferably, the antioxidant, antidepressant and anti-stress composition includes a dermis extract, and 0.1 to 20 parts by weight of a red pepper leaf extract based on 100 parts by weight of the dermis extract; It may be one comprising 5 to 50 parts by weight of sagebrush and 0.1 to 20 parts by weight of chazugi extract.
상기 범위에 의하는 경우 각 추출물의 상호 작용에 의한 상승효과로 항산화, 항우울 및 항스트레스 효과가 크게 상승할 수 있다. 따라서 보다 적은 함량으로 높은 효과를 낼 수 있으며, 장기간 복용하는 경우에도 세포독성 기타 부작용의 문제가 없다.According to the above range, the antioxidant, antidepressant and anti-stress effects may be significantly increased due to the synergistic effect by the interaction of each extract. Therefore, it can produce a high effect with a smaller content, and there is no problem of cytotoxicity and other side effects even when taken for a long time.
더 바람직하게 상기 항산화, 항우울 및 항스트레스용 조성물은 진피 추출물을 포함하고, 상기 진피 추출물 100 중량부에 대하여 고춧잎 추출물 0.1 내지 20 중량부; 범꼬리풀 5 내지 50 중량부; 차즈기 추출물 0.1 내지 20 중량부; 꿀풀 추출물 0.1 내지 10 중량부; 홍설차 추출물 0.1 내지 10 중량부 및 천문동 추출물 0.1 내지 10 중량부를 포함하는 것일 수 있다.More preferably, the antioxidant, antidepressant and anti-stress composition comprises a dermis extract, 0.1 to 20 parts by weight of a red pepper leaf extract based on 100 parts by weight of the dermis extract; 5 to 50 parts by weight of sagebrush; 0.1 to 20 parts by weight of chazugi extract; 0.1 to 10 parts by weight of Lamiaceae extract; It may include 0.1 to 10 parts by weight of red snow tea extract and 0.1 to 10 parts by weight of Cheonmundong extract.
상기 "꿀풀"은 전국의 산과 들에 흔하게 자라는 여러해살이풀로 중국과 일본에도 분포한다. 뿌리줄기가 있다. 줄기는 붉은색이 돌며, 털이 많고, 높이 20-60cm다. 잎은 마주나며, 난형 또는 난상 타원형, 가장자리가 밋밋하거나 톱니가 조금 있다. 꽃은 5-7월에 줄기 끝의 수상꽃차례에 빽빽이 달리며, 보라색, 분홍색, 흰색, 입술 모양이다. 꽃받침은 입술 모양, 5갈래로 갈라진다. 화관은 아랫입술이 3갈래로 갈라진다. 수술은 4개, 2개가 길다. 열매는 소견과이며, 4개로 갈라지고, 노란빛이 도는 갈색으로 익는다.The "Lamiaceae" is a perennial herb commonly grown in mountains and fields across the country, and is also distributed in China and Japan. There is a rhizome. Stems are reddish, hairy, and 20-60cm tall. The leaves are opposite, ovate or ovate oval, with a flat edge or some serrations. Flowers are densely hung on the inflorescence at the tip of the stem in May-July, and are purple, pink, white, and lip-shaped. The calyx is lip-shaped, divided into 5 parts. The lower lip of the corolla is divided into three parts. Stamens 4, 2 are long. The fruit is a soybean, split into 4, and ripens to yellowish brown.
상기 "홍설차"(Snow Tea, 紅雪茶)는 고산지대의 향나무 고목에서 자생하는 이끼류 식물을 건조한 것을 말한다.The "Snow Tea" (Snow Tea, 紅雪茶) refers to a dried moss plant that grows wild in an old juniper tree in an alpine region.
상기 "천문동"은 바닷가에서 자라며, 뿌리줄기는 짧고 양끝이 뾰족한 원기둥 모양의 많은 뿌리가 사방으로 퍼진다. 줄기의 밑부분은 달걀 모양의 비늘 조각이 있다. 줄기는 녹색으로 길이 1 내지 2m에 달하며 덩굴성이고 잎같이 생긴 가지는 1 내지 3개씩 모여 달리며 활처럼 굽는다. 꽃은 5 또는 6월에 피고 잎겨드랑이에 1 내지 3개씩 달리며 연한 황색이고 작은꽃줄기는 중앙에 관절이 있으며 꽃잎의 길이와 비슷하다. 화피갈래조각은 황백색이고 긴 타원형이다. 꽃잎과 수술은 6개씩이고 암술대는 3개이다. 열매는 장과(漿果)로 둥글고 지름 6mm 정도이며 흰빛으로 성숙하고 검은 종자가 1개 들어 있다.The "Cheonmun-dong" grows on the seashore, and the rhizome is short and many cylindrical roots with pointed ends spread in all directions. The lower part of the stem has egg-shaped scales. Stems are green, reaching 1 to 2m in length, tendrils, and leaf-like branches run in groups of 1 to 3 and bend like a bow. Flowers bloom in May or June, hang 1 to 3 in leaf axils, light yellow, and small flower stalks have joints in the center and are similar to the length of petals. Inflorescences are yellowish-white in color and have a long oval shape. There are 6 petals and 6 stamens, and 3 styles. The fruit is a berry, round, about 6mm in diameter, matured in white, and contains 1 black seed.
상기 꿀풀 추출물, 홍설차 추출물 및 천문동 추출물을 상기 범위로 더 포함하는 경우 각 유효성분의 상호 작용으로 항산화, 항우울 및 항스트레스에 대한 추가적인 상승효과가 나타날 뿐만 아니라, 향미와 기호성이 크게 높아지는 효과를 낼 수 있다. 따라서 기호성이 우수한 식품, 향료 조성물을 널리 보급할 수 있다.When the Lamiaceae extract, red snow tea extract and Cheonmundong extract are further included in the above range, the interaction of each active ingredient not only exhibits an additional synergistic effect on antioxidant, antidepressant and antistress, but also significantly increases flavor and palatability. can pay Accordingly, it is possible to widely distribute food and fragrance compositions with excellent palatability.
본 발명의 다른 일 실시예에 따른 일반 식품은 상기 항산화, 항우울 및 항스트레스용 조성물을 포함하는 것일 수 있다.General food according to another embodiment of the present invention may include the antioxidant, anti-depressant and anti-stress composition.
이 때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 약 0.01 내지 15 중량%로 가할 수 있으며, 건강음료 조성물은 100 ㎖를 기준으로 약 0.01 내지 10g의 비율로 가할 수 있으나, 이에 제한되지 않는다.At this time, the amount of the extract in the food or beverage may be added in an amount of about 0.01 to 15% by weight of the total food weight, and the health drink composition may be added in a ratio of about 0.01 to 10g based on 100 ml, but is not limited thereto. .
본 발명의 식품 조성물이 음료 조성물인 경우, 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제 (사카린, 아스파탐 등)를 사용할 수 있으나, 이에 제한되지 않을 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖ 당 일반적으로 약 1 내지 20g의 범위일 수 있으나, 이에 제한되지 않을 수 있다.When the food composition of the present invention is a beverage composition, there is no particular limitation on the other ingredients except for containing the extract as an essential ingredient in the indicated ratio, and it may contain various flavoring agents or natural carbohydrates as additional ingredients like conventional beverages. can Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) may be used, but are not limited thereto. The ratio of the natural carbohydrate may be generally in the range of about 1 to 20 g per 100 ml of the composition of the present invention, but may not be limited thereto.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있으나, 이에 제한되지 않을 수 있다.In addition to the above, the composition of the present invention contains various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts. salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, etc., but may not be limited thereto.
그 밖에 본 발명의 조성물은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있고, 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 중요하지는 않지만 본 발명의 조성물 100 중량부 당 약 0.1 내지 약 20 중량부의 범위에서 선택될 수 있으나, 이에 제한되지 않는다.In addition, the composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages, and these components may be used independently or in combination. The proportion of these additives is not critical, but may be selected from about 0.1 to about 20 parts by weight per 100 parts by weight of the composition of the present invention, but is not limited thereto.
본 발명의 또 다른 일 실시예에 따른 기능성 식품은 상기 항산화, 항우울 및 항스트레스용 조성물을 포함하는 것일 수 있다.Functional food according to another embodiment of the present invention may include the antioxidant, anti-depressant and anti-stress composition.
본 발명에서 말하는 "기능성 식품"은 건강보조의 목적으로 특정성분을 원료로 하거나 식품원료에 들어있는 특정성분을 추출, 농축, 정제, 혼합 등의 방법으로 제조, 가공한 식품으로 건강보조식품을 포함하며, 기타, 식품성분이 갖는 생체방어, 생체리듬의 조절, 질병의 방지와 회복 등 생체조절기능을 생체에 대하여 충분히 발휘할 수 있도록 설계되고 가공된 식품으로서, 질병의 예방 및 질병의 회복 등과 관련된 기능도 갖는 것을 모두 포함하는 것으로 한다."Functional food" as used in the present invention is a food manufactured and processed by extracting, concentrating, refining, mixing, etc., a specific ingredient as a raw material for the purpose of health supplementation, or including health supplement food. In addition, it is a food designed and processed to sufficiently exert the biological control functions of the food ingredients, such as biological defense, regulation of biological rhythm, prevention and recovery of diseases, and functions related to disease prevention and recovery from diseases. It is assumed to include all that it has.
본 발명의 또 다른 일 실시예에 따른 향료는 상기 항산화, 항우울 및 항스트레스용 조성물을 포함하는 것일 수 있다.A fragrance according to another embodiment of the present invention may include the antioxidant, antidepressant and antistress composition.
상기 향료에 대한 발명의 구현을 예시하면 본 발명의 조성물은 방향제, 디퓨져, 향초, 마사지 오일, 바디 오일, 발향 램프, 아로마스틱, 스프레이제, 비누(예컨대, 미용 비누) 및 입욕제의 형태로 구현될 수 있다.When exemplifying the embodiment of the invention for the perfume, the composition of the present invention may be implemented in the form of a perfume, a diffuser, a scented candle, a massage oil, a body oil, a fragrance lamp, an aroma stick, a spray, a soap (eg, beauty soap) and a bath agent. can
일 실시예를 예시하면 본 발명의 조성물은 향수, 입욕제 또는 방향제 제형으로 구현될 수 있고, 이 경우 본 발명의 방향제 조성물은 혼합 정유 외에 방향제 제조에 통상적으로 첨가되는 성분을 더 포함할 수 있다. 이러한 성분으로는 향료, 방부제, 안정화제, 색소, 항균제, 탈취제, 살균제 등이 있다.In one embodiment, the composition of the present invention may be embodied as a perfume, a bath agent or a perfume formulation, in which case the perfume composition of the present invention may further include components commonly added to perfume manufacturing in addition to the mixed essential oil. These ingredients include fragrances, preservatives, stabilizers, colorants, antibacterial agents, deodorants, and disinfectants.
본 발명의 또 다른 일 실시예에 따른 외용제는 상기 항산화, 항우울 및 항스트레스용 조성물을 포함하는 것일 수 있다.The external preparation according to another embodiment of the present invention may include the antioxidant, antidepressant and antistress composition.
상기 외용제는 모발, 피부 등에 도포할 수 있는 형태의 제형으로 제조되는 것을 의미한다. 또한 본 발명에서 외용제는 의약외품의 외용제에 한정하는 것은 아니며, 화장료를 포함한다. 예를 들어, 바디 로션, 샴푸, 헤어 린스, 헤어 컨디셔너, 헤어 트리트먼트, 발한 억제제, 스킨 로션, 스킨 크림, 방취제, 향수(스프레이제 또는 훈증제), 립스틱, 립크림, 입욕제 등으로 제형될 수 있으며, 특히 스킨 로션 등의 화장품이 포함되는 것이다.The external preparation means that it is prepared in a form that can be applied to hair, skin, and the like. In addition, the external preparation in the present invention is not limited to the external preparation of quasi-drugs, and includes cosmetics. For example, it may be formulated as a body lotion, shampoo, hair conditioner, hair conditioner, hair treatment, antiperspirant, skin lotion, skin cream, deodorant, perfume (spray or fumigant), lipstick, lip cream, bath agent, etc. In particular, cosmetics such as skin lotions are included.
본 발명은 진피 추출물을 포함하면서 항산화 효과를 나타낼 뿐만 아니라 스트레스 저감 효과와 우울증 예방 및 개선효과를 나타낼 수 있는 천연물 기반의 항산화, 항우울 및 항스트레스용 조성물을 제공한다.The present invention provides a composition for antioxidants, antidepressants and antistresses based on natural products that can exhibit not only an antioxidant effect while containing a dermis extract but also a stress reduction effect and a depression prevention and amelioration effect.
본 발명은 천연물을 기반으로 부작용의 문제없이 항산화, 항우울, 항스트레스 등의 효과를 나타낼 수 있도록 하면서 장기간 복용 또는 사용할 수 있는 조성물을 제공한다.The present invention provides a composition that can be taken or used for a long time while being able to exhibit effects such as antioxidant, antidepressant, and anti-stress without the problem of side effects based on natural products.
본 발명은 상기 조성물을 포함하는 일반 식품, 건강기능식품, 기호성 향료 등을 제공한다.The present invention provides a general food, a health functional food, a palatable fragrance, etc. comprising the composition.
도 1은 본 발명의 일 실시예에 따른 조성물의 항산화 효과에 관한 것이다.
도 2는 본 발명의 일 실시예에 따른 조성물의 항산화 효과에 관한 것이다.1 relates to the antioxidant effect of a composition according to an embodiment of the present invention.
2 is related to the antioxidant effect of the composition according to an embodiment of the present invention.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, embodiments of the present invention will be described in detail so that those of ordinary skill in the art can easily carry out the present invention. However, the present invention may be embodied in several different forms and is not limited to the embodiments described herein.
[제조예: 식물 추출물의 제조][Preparation Example: Preparation of plant extract]
1. 진피 추출물의 제조1. Preparation of Dermal Extract
동결건조된 진피를 3g을 15ml 튜브(tube)에 1mg을 넣고, 70% 에탄올(ethanol)을 10ml를 다시 넣었다. 시료를 rounded mixed machine에서 18 시간동안 넣고 혼합, 추출하였다. 추출 후 3000rpm, 10분 원심분리 후 상층액만 채취하였다. 이렇게 채취된 상층액에 포함된 에탄올(ethanol)을 40℃ 고온에서 증발시켰다. 그리고 남은 시료는 동결건조 시켜두었다. 본 실험에 사용한 진피 추출물(CUE)은 진피의 원재료에서 수득률은 8.4%로 추출되었다.3g of the lyophilized dermis was put into 1mg of a 15ml tube, and 10ml of 70% ethanol was added again. The sample was put in a rounded mixed machine for 18 hours, mixed and extracted. After extraction, only the supernatant was collected after centrifugation at 3000 rpm for 10 minutes. Ethanol contained in the supernatant collected in this way was evaporated at a high temperature of 40 °C. And the remaining sample was freeze-dried. The dermis extract (CUE) used in this experiment was extracted with a yield of 8.4% from the raw material of the dermis.
2. 기타 식물 추출물의 제조2. Preparation of other plant extracts
고춧잎 추출물(AE)은 건조 및 분쇄된 고춧잎을 70% 에탄올(ethanol)로 추출하여 제조하였다. 또한 범꼬리풀 추출물(BE), 차즈기 추출물(CE), 꿀풀 추출물(DE), 홍설차 추출물(EE) 및 천문동 추출물(FE) 역시 위와 동일한 방법으로 제조하였다. Red pepper leaf extract (AE) was prepared by extracting dried and pulverized red pepper leaves with 70% ethanol (ethanol). In addition, beomtail extract (BE), chazugi extract (CE), lamifolia extract (DE), red snow tea extract (EE) and cheonmundong extract (FE) were also prepared in the same manner as above.
3. 복합 추출물의 제조3. Preparation of Complex Extracts
각 추출물의 혼합에 따른 상승효과를 확인하기 위하여 하기의 [표 1]과 같은 조성에 따라 각 추출물을 혼합하여 복합 추출물을 제조하였다.In order to confirm the synergistic effect of mixing each extract, each extract was mixed according to the composition shown in Table 1 below to prepare a complex extract.
(단위: 중량부)(Unit: parts by weight)
[실험예: 항산화, 항우울, 항스트레스 테스트][Experimental example: antioxidant, antidepressant, anti-stress test]
1. 동물 실험방법 및 동물 그룹1. Animal Test Methods and Animal Groups
(1) 동물 실험 방법(1) Animal testing method
체중 100 내지 120 g인 4주령 Spraque-Dawley 흰쥐(한국중앙동물, 경기도, 한국)을 암컷 30마리를 구입하여 사육실 온도는 20±2 ℃, 습도는 55-60 %를 유지하여 사육하였다. 주간-야간 주기는 12시간으로 조절하였다. 일반배합사료(PMI Nutrition LLC. Manufactured in the USA. 5L79) 및 음수는 제한을 두지 않았고 일주일간 사육실 환경에 적응기를 가진 후 실험을 실시하였다. 실험은 모두 주간에 실시하였다.Thirty female 4-week-old Spraque-Dawley rats (Korea Central Animal, Gyeonggi-do, Korea), weighing 100 to 120 g, were purchased and bred at a temperature of 20 ± 2 °C and humidity of 55-60%. The day-night cycle was adjusted to 12 hours. There were no restrictions on general formula feed (PMI Nutrition LLC. Manufactured in the USA. 5L79) and drinking water, and the experiment was conducted after a period of adaptation to the breeding room environment for a week. All experiments were conducted during the day.
(2) 동물 그룹(2) group of animals
그룹당 5마리씩 3그룹으로 나누어 진행하였다. 1그룹은 control은 구강으로 물을 투여한 그룹이며 2그룹은 진피 15mg/150g(rat weigh)를 경구 투여하였다.5 animals per group were divided into 3 groups. In
2. 항산화 테스트2. Antioxidant test
(1) DPPH 라디칼 소거 활성 측정 - 진피의 보유 항산화(1) Measurement of DPPH radical scavenging activity - Retained antioxidant in the dermis
DPPH (2,2-diphenyl-1-picrylhydrazyl) DPPH (2,2-diphenyl-1-picrylhydrazyl)
본 실험에 사용된 DPPH(Diphenylpicryl hydrazyl)의 hydrazyl은 질소원자가 불안정한 상태에 있으므로 쉽게 수소원자를 받아들이는 성질을 가지고 있어 항산화성 물질과 반응하여 수소원자를 받아들임으로써 자체의 정색성을 잃는 것을 이용하였다. 진피 물질별 농축 건조물을 0.05, 0.1, 0.2, 0.5, 1 mg/ml 5가지 농도로 조제한 용액 0.1 ml(control: 99.5% ethanol)에 0.2 mM DPPH용액(99.5% ethanol) 1.9 ml를 가하였다. Vortex mixer로 10초간 진탕한 후 37 ℃에서 30분 동안 incubation시켰다. 이후 spectrophotometer를 이용하여 517 nm에서 흡광도를 측정하였다. The hydrazyl of DPPH (Diphenylpicryl hydrazyl) used in this experiment has the property of easily accepting hydrogen atoms because the nitrogen atom is in an unstable state. 1.9 ml of 0.2 mM DPPH solution (99.5% ethanol) was added to 0.1 ml (control: 99.5% ethanol) of a solution prepared in 5 concentrations of 0.05, 0.1, 0.2, 0.5, and 1 mg/ml of concentrated dry matter for each dermal material. After shaking for 10 seconds with a vortex mixer, it was incubated at 37 °C for 30 minutes. Then, the absorbance was measured at 517 nm using a spectrophotometer.
양성 대조 약물로는 L-ascorbic acid를 0.05, 0.1, 0.5, 1 mg/ml(99.5% ethanol)의 5가지 농도로 조제하여 측정하였다. 각 시료의 항산화작용은 DPPH에 대한 % Antioxidant activity (Electron donating ability)으로 나타내었다. As a positive control drug, L-ascorbic acid was prepared at 5 concentrations of 0.05, 0.1, 0.5, and 1 mg/ml (99.5% ethanol) and measured. The antioxidant activity of each sample was expressed as % Antioxidant activity (electron donating ability) against DPPH.
그 결과를 하기의 [도 1]에 나타내었다.The results are shown in [Fig. 1] below.
(2) Xanthine oxidase 저해활성 측정(2) Xanthine oxidase inhibitory activity measurement
시료용액 0.1 ml와 pH 7.5의 0.1 M potassium phosphate buffer 0.6 ml에 2 mM xanthine을 녹인 기질액 0.2 ml를 첨가하고 0.2 unit/ml xanthine oxidase 0.1ml를 가하여 37℃에서 5분간 반응시킨 후 1 N HCl 1 ml를 가하여 반응을 종료시킨 다음, 반응액 중에 생성된 uric acid를 292 nm에서 흡광도를 측정하였다. Xanthin oxidase저해 활성은 시료용액의 첨가군과 무첨가군의 흡광도 감소율로 나타내었다.In 0.1 ml of sample solution and 0.6 ml of 0.1 M potassium phosphate buffer of pH 7.5, 0.2 ml of substrate solution in which 2 mM xanthine was dissolved was added, 0.2 unit/ml xanthine oxidase 0.1ml was added, and reacted at 37°C for 5 minutes, followed by 1
Xanthine oxidase는 모든 purine의 terminal oxidation에서 rate-limiting enzyme으로 작용하며 superoxide radical이나 hydrogenperoxide와 같은 산화제의 source로서 작용하는 효소이다. Xanthine/ xanthine oxidase의 효소에 의한 superoxide음이온 저해작용은 superoxide 음이온 소거작용과 xanthine oxidase 효소 저해에 의해 나타나며 free radical의 생성 억제를 통해 생물학적으로 중요한 의미를 갖는다. 양성 대조군으로 allopurinol 50μM의 superoxide radical 소거효과를 비교하였다.Xanthine oxidase is an enzyme that acts as a rate-limiting enzyme in the terminal oxidation of all purines and as a source of oxidizing agents such as superoxide radicals and hydrogenperoxide. The inhibition of superoxide anion by the enzyme of xanthine/xanthine oxidase is indicated by the scavenging action of superoxide anion and inhibition of the xanthine oxidase enzyme, and has a biological significance by inhibiting the generation of free radicals. The superoxide radical scavenging effect of 50 μM allopurinol as a positive control was compared.
그 결과는 하기의 [도 2]에 나타내었다. 한편, 하기의 [도 2]를 참조하면 양성대조군인 allopurinol 50μM보다 진피 1mg/ml에서 약 2배 이상의 높은 소거 효과를 나타낸다는 점을 알 수 있다.The results are shown in [Fig. 2] below. On the other hand, referring to [Fig. 2] below, it can be seen that the positive control group,
3. 항우울 행동 실험(강제수영실험군, Forced Swiming Test, FST)3. Antidepressant behavior test (Forced Swimming Test, Forced Swimming Test, FST)
실험동물의 사육장에 도착 후 14일간 사육장 환경에 적응시키고 물에 적응 시키기위해 강제수영시험을 15분간 3그룹 모두 실시하여 적응시켰고 3일간 그룹별로 물(Control), 진피 추출물(CUE)을 복용시켰다. 강제수영실험 5분간 빠뜨린 후 초기에는 적극적으로 탈출하려는 모습이 보이나 곧 수면공포에 빠져 우울증의 정도에 따라 부동자세(immobility)를 유지하므로 부동시간을 측정하였다. 해당 실험을 3회 반복하였다.After the animals arrived at the kennel, they were acclimatized to the kennel environment for 14 days and acclimatized by conducting a forced swimming test for 15 minutes in all three groups to acclimatise to the water. After missing 5 minutes of the forced swimming test, it appears that they are actively trying to escape at the beginning, but they soon fall into a sleep fear and maintain an immobility according to the degree of depression, so immobility time was measured. The experiment was repeated 3 times.
한편, 그 결과를 하기의 [표 2]에 나타내었다.On the other hand, the results are shown in [Table 2] below.
(단위: 초)상기 [표 2]을 참조하면, 진피 추출물(CUE)을 경우 복용시킨 경우 물(Control)을 경구 복용시킨 경우에 비해 부동시간이 단축되는 것을 확인하였다.(Unit: seconds) Referring to [Table 2], it was confirmed that the immobility time was shortened when the dermis extract (CUE) was taken compared to the case where the water (Control) was taken orally.
4. 스트레스 개선효과 실험4. Stress improvement effect test
본 실험에 동의한 남녀 10명을 위약을 섭취한 대조군(placebo), 진피 추출물(CUE)을 섭취한 실험군으로 각 5명씩 임의로 분류하여 4주간 각각의 차음료 형태로 400 mg씩 섭취하도록 하였다. 심리적 건강 개선효과를 살펴보기 위해, 사회, 심리적 건강측정검사인 PWI (Psychosocial Well-being Index)를 섭취 전후에 실시하였다. 객관적인 비교를 위하여 대조군의 값을 10으로 고정하고, 10점 척도로 지수를 변환하여 1 내지 10의 지수로 평가하여 그 결과를 하기의 [표 3]에 나타내었다. 하기의 지수는 그 숫자가 낮을수록 스트레스 개선효과가 우수한 것이다.Ten men and women who consented to this experiment were randomly classified into a control group taking a placebo and an experimental group taking dermis extract (CUE), each of which was arbitrarily divided into 5 people each, and consumed 400 mg each in the form of tea drinks for 4 weeks. In order to examine the psychological health improvement effect, PWI (Psychosocial Well-being Index), a social and psychological health measurement test, was conducted before and after intake. For objective comparison, the value of the control group was fixed at 10, the index was converted on a 10-point scale, and the index was evaluated as an index of 1 to 10, and the results are shown in [Table 3] below. In the following index, the lower the number, the better the stress improvement effect.
(단위: 지수)(Unit: Index)
상기 [표 3]를 참조하면, 본 발명에 따른 진피 추출물을 지속적으로 사용하는 경우 스트레스 완화에 도움이 될 수 있다는 것을 알 수 있다. 특히 상기 PWI 지수에 따라 자신감 상승 및 심신의 안정감이 높아질 수 있다는 점을 알 수 있다. 따라서 상기 진피 추출물을 지속적으로 사용하는 경우 스트레스를 완화할 수 있으며, 스트레스에 의하여 발병하는 질병에 대한 예방 및 개선효과를 나타내게 할 수 있다.Referring to [Table 3], it can be seen that the continuous use of the dermis extract according to the present invention can help relieve stress. In particular, it can be seen that self-confidence and mental and physical stability can be increased according to the PWI index. Therefore, when the dermis extract is used continuously, it is possible to relieve stress, and it is possible to exhibit the prevention and improvement effect on diseases caused by stress.
4. 복합 추출물에 대한4. For complex extracts 항산화, 항우울, 항스트레스 테스트Antioxidant, antidepressant, antistress test
상기와 동일한 방법으로 복합추출물 N1 내지 N9에 대한 항산화(AO), 항우울(AP), 항스트레스(AS) 효과를 평가하였다. 또한 진피 추출물(CUE)에 비하여 상승효과가 나타나는지 확인하기 위하여, CUE를 고정 값으로 하고, N1 내지 N9에 대한 활성을 비교하였다. Antioxidant (AO), antidepressant (AP), and antistress (AS) effects were evaluated for the complex extracts N1 to N9 in the same manner as above. In addition, in order to determine whether a synergistic effect appears compared to the dermis extract (CUE), the CUE was set as a fixed value, and the activities for N1 to N9 were compared.
따라서 객관적인 비교를 위하여 하기의 평가지수는 AO 및 AP의 경우 CUE 결과를 1로 고정하고, 및 N1 내지 N9의 값을 CUE과 비교하여 1 내지 10의 지수로 변환하여 나타내었다. 상기 지수에서 AO 및 AP는 그 숫자가 높을수록 효과가 우수한 것이다. 한편, AO 및 AP에서 1로 1미만으로 계산되는 지수도 1로 표기하였다. 따라서 AO 및 AP에서 1로 표기되는 지수는 상승효과가 없거나, CUE 단독 사용보다 그 효과가 떨어지는 것이다.Therefore, for objective comparison, the following evaluation indices fixed the CUE result to 1 in the case of AO and AP, and converted the values of N1 to N9 into indices of 1 to 10 by comparing them with the CUE. AO and AP in the above index, the higher the number, the better the effect. On the other hand, indices calculated as 1 and less than 1 in AO and AP are also denoted as 1. Therefore, the index indicated by 1 in AO and AP does not have a synergistic effect, or its effect is inferior to that of CUE alone.
또한, AS의 경우 CUE의 결과를 10으로 고정하고, 및 N1 내지 N9의 값을 CUE 과 비교하여 1 내지 10의 지수로 변환하여 나타내었다. 상기 지수에서 AS는 그 숫자가 낮을수록 효과가 우수한 것이다. 한편, AS에서 1로 10을 초과하는 것으로 계산되는 지수도 10로 표기하였다. 따라서 AS에서 10으로 표기되는 지수는 상승효과가 없거나, CUE 단독 사용보다 그 효과가 떨어지는 것이다.In addition, in the case of AS, the CUE result is fixed at 10, and the values of N1 to N9 are compared with the CUE and converted into an exponent of 1 to 10. As for AS in the above index, the lower the number, the better the effect. On the other hand, the index calculated to exceed 10 by 1 in AS is also denoted as 10. Therefore, the index expressed as 10 in AS does not have a synergistic effect, or its effect is inferior to that of using CUE alone.
그 결과를 하기의 [표 4]에 나타내었다.The results are shown in [Table 4] below.
(단위: 지수)(Unit: Index)
상기 [표 4]를 참조하면, N1의 경우 복합 추출물에 대한 상승효과가 없었으며, N5의 경우 CUE 이외의 다른 추출물의 상대적으로 증가하면서 유의미한 상승효과가 없으며, 일부 지수는 CUE 보다 낮아지는 것을 확인할 수 있었다.Referring to [Table 4], in the case of N1, there was no synergistic effect on the complex extract, and in the case of N5, there was no significant synergistic effect while relatively increasing other extracts other than CUE, and it was confirmed that some indices were lower than CUE. could
다만 N2 내지 N4와 같이 고춧잎 추출물, 범꼬리풀 추출물 및 차즈기 추출물이 특정 함량범위로 포함되는 실시예에 의하는 경우 각 추출물에 포함된 활성성분의 상호 조합으로 진피 추출물을 단독으로 사용하는 경우에 비하여 상승효과를 나타낸다는 것을 알 수 있다. 또한 N3의 경우 항산화 활성, 항우울 활성 및 항스트레스 활성이 크게 향상되는 것을 알 수 있었다.However, as in N2 to N4, according to the embodiment in which the red pepper leaf extract, the sagebrush extract and the chazugi extract are included in a specific content range, compared to the case of using the dermis extract alone as a mutual combination of the active ingredients included in each extract It can be seen that there is a synergistic effect. In addition, in the case of N3, it was found that antioxidant activity, antidepressant activity and antistress activity were significantly improved.
한편, N7 및 N8에 의하는 경우 추가적인 상승효과를 나타낼 수 있다는 점을 확인할 수 있다. 따라서 N7 및 N8에 의하는 경우 보다 적은 함량으로 매우 뛰어난 항산화 활성, 항우울 활성 및 항스트레스 활성을 나타낼 수 있고, 장기간 지속적인 복용 또는 사용이 가능하다는 점을 확인할 수 있다.On the other hand, it can be confirmed that in the case of N7 and N8, an additional synergistic effect can be exhibited. Therefore, it can be confirmed that, in the case of N7 and N8, very excellent antioxidant activity, antidepressant activity and anti-stress activity can be exhibited with a smaller content, and continuous administration or use for a long period of time is possible.
5. 기호성 테스트5. palatability test
상기 진피 추출물(CUE) 및 N1 내지 N9을 차형태로 가공하여 각 시음자에게 향미와 맛을 기초로 한 기호도를 평가하도록 하였다. 시음자는 위 스트레스 완화효과를 평가한 10인이 진피 추출물에 대한 기호도와 비교하여 N1 내지 N9의 기호성을 1 내지 10의 지수로 평가하도록 하였다. 평가된 결과 값을 평균으로 하여 하기의 [표 5]에 나타내었다. 하기의 평가 값은 소수점을 반올림하였으며, 숫자가 높을수록 기호성이 우수한 것이다.The dermis extract (CUE) and N1 to N9 were processed into tea form, and each taster was asked to evaluate the preference based on flavor and taste. The tasters were asked to evaluate the palatability of N1 to N9 on an index of 1 to 10 by comparing the taste for the dermis extract by 10 people who evaluated the gastric stress relieving effect. The evaluated result values were taken as an average and are shown in [Table 5] below. The following evaluation values were rounded off with a decimal point, and the higher the number, the better the palatability.
상기 [표 5]를 참조하면, N1 내지 N5에 의하는 경우 CUE에 비하여 유사하거나 낮은 정도의 기호성이 나타난다는 점을 알 수 있다. 한편, N7 내지 N9에 의하는 경우 향미와 맛이 개선되는 효과가 나타나는 점을 알 수 있는데, 특히 N7 및 N8의 향미와 맛의 개선정도가 우수하다.Referring to [Table 5], it can be seen that, in the case of N1 to N5, a similar or lower degree of palatability compared to the CUE appears. On the other hand, in the case of N7 to N9, it can be seen that the effect of improving the flavor and taste appears, and in particular, the degree of improvement in flavor and taste of N7 and N8 is excellent.
따라서 상기 범위에 의하는 경우 기호성이 뛰어난 식품, 향료 조성물로 제공할 수 있다는 점을 알 수 있다.Therefore, it can be seen that, in the case of the above range, it can be provided as a food and flavoring composition with excellent palatability.
이상에서 본 발명의 바람직한 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고 다음의 청구범위에서 정의하고 있는 본 발명의 기본 개념을 이용한 당업자의 여러 변형 및 개량 형태 또한 본 발명의 권리범위에 속하는 것이다.Although preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements by those skilled in the art using the basic concept of the present invention as defined in the following claims are also provided. is within the scope of the
Claims (9)
고춧잎 추출물, 범꼬리풀 추출물, 차즈기 추출물, 꿀풀 추출물, 홍설차 추출물 및 천문동 추출물을 더 포함하고,
상기 진피 추출물 100 중량부에 대하여, 고춧잎 추출물 0.1 내지 20 중량부, 범꼬리풀 추출물 5 내지 50 중량부, 차즈기 추출물 0.1 내지 20 중량부, 꿀풀 추출물 0.1 내지 10 중량부, 홍설차 추출물 0.1 내지 10 중량부 및 천문동 추출물 0.1 내지 10 중량부를 포함하는 것으로,
항산화 활성 및 스트레스 개선 효과가 우수한
우울증의 예방 또는 개선용 조성물.dermis extract;
Further comprising a red pepper leaf extract, sagebrush extract, chazugi extract, Lamiaceae extract, red snow tea extract and cheonmundong extract,
Based on 100 parts by weight of the dermis extract, 0.1 to 20 parts by weight of a red pepper leaf extract, 5 to 50 parts by weight of an oleracea extract, 0.1 to 20 parts by weight of a tea extract, 0.1 to 10 parts by weight of an extract of Lamiaceae, 0.1 to 10 parts by weight of a red snow tea extract As containing parts and 0.1 to 10 parts by weight of Cheonmundong extract,
Excellent antioxidant activity and stress-reducing effect
A composition for preventing or improving depression.
상기 추출물은 물, C1 내지 C6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 추출 용매를 이용하여 추출되는 것인
항산화 활성 및 스트레스 개선 효과가 우수한
우울증의 예방 또는 개선용 조성물.The method of claim 1,
The extract is extracted using an extraction solvent selected from the group consisting of water, C 1 to C 6 lower alcohols and mixtures thereof.
Excellent antioxidant activity and stress-reducing effect
A composition for preventing or improving depression.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200021186A KR102414267B1 (en) | 2020-02-20 | 2020-02-20 | For antioxidant, antidepressant and antistress compositions comprising citrus unshiu peel extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200021186A KR102414267B1 (en) | 2020-02-20 | 2020-02-20 | For antioxidant, antidepressant and antistress compositions comprising citrus unshiu peel extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210106620A KR20210106620A (en) | 2021-08-31 |
KR102414267B1 true KR102414267B1 (en) | 2022-06-29 |
Family
ID=77489397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200021186A KR102414267B1 (en) | 2020-02-20 | 2020-02-20 | For antioxidant, antidepressant and antistress compositions comprising citrus unshiu peel extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102414267B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006327970A (en) * | 2005-05-25 | 2006-12-07 | Daicho Kikaku:Kk | Digestive apparatus agent and anti-stress agent |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07252161A (en) * | 1994-03-11 | 1995-10-03 | Pola Chem Ind Inc | Active oxygen eliminating agent and composition containing the agent |
KR100513489B1 (en) | 2002-04-01 | 2005-09-09 | 퓨리메드 주식회사 | Extract of Nelumbinis Semen for the treatment of depression |
KR100909574B1 (en) * | 2009-04-06 | 2009-07-29 | 주식회사 코리아나화장품 | Cosmetic Composition Comprising Polygonum bistorta extract for Free Radical Scavenging Activity |
KR101146634B1 (en) * | 2009-09-16 | 2012-05-16 | 재단법인 제주테크노파크 | Fraction of Citrus unshiu Fruit Peel Extract and Use Thereof |
KR20130086459A (en) | 2012-01-25 | 2013-08-02 | 경희대학교 산학협력단 | Pharmaceutical composition for rapid acting prevention and treatment of depression comprising extract of zizyphus spinosa semen as an active ingredient |
KR102066845B1 (en) * | 2018-01-19 | 2020-01-16 | 안동대학교 산학협력단 | Plasma-treated pepper leaf extreact with improved anti-inflammatory effect and manufacturing method thereof |
-
2020
- 2020-02-20 KR KR1020200021186A patent/KR102414267B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006327970A (en) * | 2005-05-25 | 2006-12-07 | Daicho Kikaku:Kk | Digestive apparatus agent and anti-stress agent |
Also Published As
Publication number | Publication date |
---|---|
KR20210106620A (en) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100910747B1 (en) | Herb medicine mixture extracts having antifungal, antiacne, skin calming, moisturizing and sebum controlling activities | |
KR20200106577A (en) | Composition for anti-oxidant, anti-inflammatory and relieving swelling containing plant complex extracts | |
Kozak et al. | Health properties of selected herbal plants | |
KR101407659B1 (en) | A composition for inhibiting testosterone 5-alpha reductase | |
JP2012214414A (en) | β-SECRETASE INHIBITOR, AND FOOD AND DRINK INCLUDING β-SECRETASE INHIBITOR, AND INHIBITION RATE MEASURING METHOD TO MEASURE INHIBITION RATE THEREOF | |
KR100989944B1 (en) | A mixed herb medicine extracts having antioxidant whitening activity | |
KR20160081205A (en) | Composition comprising extract of hydrangea serrata for preventing and improving obesity | |
KR102093990B1 (en) | Comppsition comprising mori folium extracts for preventing, treating muscular dystrophy | |
KR102414267B1 (en) | For antioxidant, antidepressant and antistress compositions comprising citrus unshiu peel extract | |
KR102496534B1 (en) | Functional food composition containing olive tree extract with excellent antioxidant activity as an active ingredient | |
Ravindran et al. | Other herbs and spices: achiote to Szechuan pepper | |
KR102319379B1 (en) | Composition comprising banana leaf extract for antioxidant, antidepressant and antistress | |
KR102319382B1 (en) | For antioxidant, antidepressant and antistress compositions comprising boswellia | |
KR102309180B1 (en) | For antioxidant, antidepressant and antistress compositions comprising maca | |
KR102537835B1 (en) | Composition comprising fraxinus rhynchophylla extract for antidepressant and antistress | |
KR102533832B1 (en) | Functional food composition excellent in improving depression and relieving stress index | |
KR102345335B1 (en) | Anti-stress compositon containing lepidium apetalum extracts | |
KR20110029280A (en) | A soap composition for traditional oriental medicine | |
KR20210151478A (en) | Composition for anti-inflammation comprising extract from Tartary buckwheat | |
KR102232658B1 (en) | A pharmaceutical composition comprising pedicularis resupinata extract for depression or stress relief, and a composition for improving cognitive function | |
KR102020644B1 (en) | Composition for preventing or alleviating stress-involved disease | |
KR102433007B1 (en) | Composition for preventing and treating of neuropathic pain containing saussurea neoserrata extract | |
KR20170121033A (en) | Cosmetic composition for lips containing herbal ingredients necessary for women by age group | |
KR102528157B1 (en) | A Method for Preparing Liquid Eyelash Nutritional Supplements Containing a Large Amount of Black Beans and, the Liquid Nutritional Supplements for Eyelashes That is Produced through the Method | |
KR102434150B1 (en) | Compositions for inner beauty containing cirsium japonicum extract as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |